{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:09:48Z","timestamp":1791925788688,"version":"4.3.4"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T00:00:00Z","timestamp":1447372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Wroclaw Research Centre","award":["POIG.01.01.02-02-003\/08"],"award-info":[{"award-number":["POIG.01.01.02-02-003\/08"]}]},{"name":"European Regional Development Found"},{"name":"Polish Ministry of Science and Higher Education","award":["IP2014 007373"],"award-info":[{"award-number":["IP2014 007373"]}]},{"name":"Wroclaw Center of Biotechnology"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jconrel.2015.11.015","type":"journal-article","created":{"date-parts":[[2015,11,14]],"date-time":"2015-11-14T13:15:15Z","timestamp":1447506915000},"page":"515-528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"PA","title":["Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody"],"prefix":"10.1016","volume":"220","author":[{"given":"Justyna M.","family":"Meissner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-7239","authenticated-orcid":false,"given":"Monika","family":"Toporkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Czogalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucyna","family":"Matusewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazimierz","family":"Kuliczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander F.","family":"Sikorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2015.11.015_bb0005","doi-asserted-by":"crossref","first-page":"524308","DOI":"10.1155\/2012\/524308","article-title":"The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias","volume":"2012","author":"Tzifi","year":"2012","journal-title":"Adv. Hematol"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0010","first-page":"5","article-title":"Cytogenetic abnormalities in chronic lymphocytic leukemia","volume":"42","author":"Karnolsky","year":"2000","journal-title":"Folia Med."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0015","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1046\/j.1432-1033.2003.03555.x","article-title":"Antisense technologies. Improvement through novel chemical modifications","volume":"270","author":"Kurreck","year":"2003","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0020","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/nnm.10.6","article-title":"ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation","volume":"5","author":"Wang","year":"2010","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/138920107782109985","article-title":"Antisense technology: a selective tool for gene expression regulation and gene targeting","volume":"8","author":"Sahu","year":"2007","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00249-006-0092-4","article-title":"Gene delivery by cationic lipid vectors: overcoming cellular barriers","volume":"36","author":"Zuhorn","year":"2007","journal-title":"Eur. Biophys. J."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0035","series-title":"Frontiers Nanotherapy","first-page":"139","article-title":"Synthetic vectors for genetic drug delivery, nanocarrier technologies","author":"Wyrozumska","year":"2006"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0040","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1357-4310(99)01638-X","article-title":"Antisense therapeutics: is it as simple as complementary base recognition?","volume":"6","author":"Agrawal","year":"2000","journal-title":"Mol. Med. Today"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2230-973X.108958","article-title":"Novel gene delivery systems","volume":"3","author":"Manjila","year":"2013","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0050","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2174\/1381612053382133","article-title":"The design of cationic lipids for gene delivery","volume":"11","author":"Martin","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0055","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jconrel.2011.10.009","article-title":"Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design","volume":"158","author":"Buyens","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2478\/s11658-006-0049-8","article-title":"Higly fusogenic cationic liposomes transiently permeabilize the plasma membrane of HeLa cells","volume":"12","author":"Stebelska","year":"2007","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/hum.2006.17.117","article-title":"Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery","volume":"17","author":"Pirollo","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jconrel.2007.11.005","article-title":"Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab\u2019 fragments and single chain Fv","volume":"126","author":"Cheng","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0075","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1021\/mp900316a","article-title":"Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells","volume":"7","author":"Hu","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0080","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.biomaterials.2007.12.015","article-title":"Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets","volume":"29","author":"Huang","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0085","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1039\/c0ib00013b","article-title":"Homing peptides as targeted delivery vehicles","volume":"2","author":"Laakkonen","year":"2010","journal-title":"Integr. Biol."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0090","doi-asserted-by":"crossref","first-page":"19347","DOI":"10.1073\/pnas.1115945108","article-title":"In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles","volume":"108","author":"Chan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2478\/s11658-010-0023-3","article-title":"The selection of aptamers specific for membrane molecular targets","volume":"16","author":"Janas","year":"2011","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0100","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1021\/nn800275r","article-title":"Self-assembled lipid\u2013polymer hybrid nanoparticles: a robust drug delivery platform","volume":"2","author":"Zhang","year":"2008","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0105","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.drudis.2008.04.013","article-title":"DARPins: a new generation of protein therapeutics","volume":"13","author":"Stumpp","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0110","first-page":"6551","article-title":"In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice","volume":"9","author":"Gabizon","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0115","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijpharm.2010.02.008","article-title":"Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells","volume":"390","author":"Zheng","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0120","first-page":"1399","article-title":"Towards a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges","volume":"10","author":"Toporkiewicz","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0125","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/978-1-60761-609-2_17","article-title":"Targeting of nanoparticles: folate receptor","volume":"624","author":"Kularatne","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0005-2736(95)00085-H","article-title":"A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells","volume":"1237","author":"Allen","year":"1995","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0135","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1063\/1.1678153","article-title":"Analysis of macromolecular polydispersity in intensity correlation spectroscopy: the method of cumulants","volume":"57","author":"Koppel","year":"1972","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0145","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1208\/s12248-012-9330-0","article-title":"Challenges in development of targeted liposomal therapeutics","volume":"14","author":"Sawant","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0150","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4161\/15384047.2014.987009","article-title":"Liposome-coated lipoplex-based carrier for antisense oligonucleotides","volume":"16","author":"Wyrozumska","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0155","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/jnci\/djh221","article-title":"Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs","volume":"96","author":"Brignole","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0160","first-page":"4595","article-title":"Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models","volume":"9","author":"Pastorino","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0165","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jnci\/92.3.253","article-title":"Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects","volume":"92","author":"Pagnan","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0170","first-page":"855","article-title":"Oblimersen for the treatment of patients with chronic lymphocytic leukemia","volume":"3","author":"Cheson","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0175","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","article-title":"Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia","volume":"23","author":"O'Brien","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1189\/jlb.72.1.83","article-title":"Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN","volume":"72","author":"Jahrsdorfer","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0185","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/nbt1042","article-title":"Role of toll-like receptors in antisense and siRNA [corrected]","volume":"22","author":"Agrawal","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/oli.2006.16.83","article-title":"G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice","volume":"16","author":"Gekeler","year":"2006","journal-title":"Oligonucleotides"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.cgt.7700986","article-title":"Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy","volume":"14","author":"Kim","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0200","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/17435889.3.5.703","article-title":"Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats","volume":"3","author":"Longmire","year":"2008","journal-title":"Nanomedicine (London)"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0205","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrd2591","article-title":"Strategies in the design of nanoparticles for therapeutic applications","volume":"9","author":"Petros","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0210","first-page":"2431","article-title":"Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine","volume":"52","author":"Allen","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0215","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/138920012798356934","article-title":"PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery","volume":"13","author":"Milla","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0220","first-page":"297","article-title":"Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential","volume":"1","author":"Immordino","year":"2006","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0225","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.phrs.2010.03.005","article-title":"Targeting nanoparticles to cancer","volume":"62","author":"Wang","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0230","doi-asserted-by":"crossref","first-page":"E128","DOI":"10.1208\/aapsj0902015","article-title":"Targeted pharmaceutical nanocarriers for cancer therapy and imaging","volume":"9","author":"Torchilin","year":"2007","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0235","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/bcr2328","article-title":"Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer","volume":"11","author":"Foster","year":"2009","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0240","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1097\/JTO.0000000000000285","article-title":"Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II study","volume":"9","author":"Natale","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0245","article-title":"Randomized phase II study of the X-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)","author":"Lee","year":"2014","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0250","series-title":"A Status Update of Modified Oligonucleotides for Chemotherapeutics Applications, Curr Protoc Nucleic Acid Chem Chapter 4","first-page":"1","author":"Sanghvi","year":"2011"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0255","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/187569211796957584","article-title":"Targeting Bcl-2 in herceptin-resistant breast cancer cell lines","volume":"9","author":"Crawford","year":"2011","journal-title":"Curr. Pharmacogenomics Pers. Med."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0260","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.1093\/nar\/gks294","article-title":"Delivery of chemo-sensitizing siRNAs to HER2+\u2212breast cancer cells using RNA aptamers","volume":"40","author":"Thiel","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0265","doi-asserted-by":"crossref","first-page":"15621","DOI":"10.1074\/jbc.273.25.15621","article-title":"Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides","volume":"273","author":"Meyer","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0270","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2002-06-1685","article-title":"Specific inhibition of bcr-abl gene expression by small interfering RNA","volume":"101","author":"Scherr","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0275","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/asheducation-2011.1.243","article-title":"Novel antibody-based therapies for acute lymphoblastic leukemia","volume":"2011","author":"Hoelzer","year":"2011","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0280","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood-2012-01-407742","article-title":"Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia","volume":"121","author":"Yu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2015.11.015_bb0285","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0026-895X(25)08861-3","article-title":"Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology","volume":"41","author":"Gao","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0290","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1073\/pnas.91.13.5957","article-title":"Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides","volume":"91","author":"Perez","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0295","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1158\/1078-0432.CCR-03-0376","article-title":"Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes","volume":"10","author":"Sapra","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2015.11.015_bb0300","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/1078-0432.CCR-03-0041","article-title":"Improved therapeutic responses in a xenograft model of human B lymphoma (namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or fab\u2019 fragments","volume":"10","author":"Sapra","year":"2004","journal-title":"Clin. Cancer Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591530239X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591530239X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T11:55:08Z","timestamp":1748692508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836591530239X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":60,"alternative-id":["S016836591530239X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.11.015","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2015.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}